Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

Abstract

Naporafenib plus trametinib showed promising preliminary antitumor activity in patients with <i>NRAS</i>-mutant melanoma. Prophylactic strategies aimed to lower the incidence of skin-related events are under investigation.